GABA Resurgence: Pharma Foods International Releases Study Proving Unexpected Benefit to Muscle Growth From a Valued Amino Acid
Pharma Foods International Co. Ltd . has made available for publication its first-ever study proving that supplementing a post-exercise whey protein regimen with their naturally-produced flagship product PharmaGABATM produces an increase in the body’s already existing resting serum growth hormone level, consequently boosting the formation of lean muscle mass. This officially opens a path connecting regular intake of GABA to a naturally beneficial and balanced nutritional profile for the athletic lifestyle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190828005023/en/
Change in whole body lean mass for 12 wk measured by DXA (Photo: Business Wire)
GABA (γ-Aminobutyric acid) is an amino acid that functions as a key inhibitory neurotransmitter, and is central to cellular activity in the human nervous system. Although GABA’s specific anabolic effect remains undefined, what this study now proves is that oral intake of PharmaGABATM along with whey protein, a known means of stimulating skeletal muscle hypertrophy, enhances the process and produces demonstrably more lean mass than with whey protein alone.
The study looked at 26 males, aged 26 to 48, who practiced progressive-resistance weight training. The group was divided in two — all ingested 10 grams of whey protein daily, half supplemented it with 100 milligrams of PharmaGABATM. The group trained twice weekly, following a systematized circuit of weight-resistance exercises. Resting serum growth hormone was recorded in blood plasma at baseline, four, eight, and twelve weeks; while change in muscle mass was measured using dual-energy X-ray absorptiometry (DXA) at baseline and twelve weeks. The result was that while GH improved significantly for the group ingesting whey protein, the improvement quickly leveled off, whereas the addition of GABA demonstrated proliferation of GH throughout the entire period, and at the end of twelve weeks, lean mass was dramatically increased in the group taking both together.
Pharma Foods International is a leader in the production of GABA, long an admired nutritional supplement for its role in positively affecting such neural functions as relaxation, stress reduction and focus. Its PharmaGABA TM is naturally-derived using lactobacillus hilgardii, used for centuries in the preparation of foods like Korean kimchi. PharmaGABA TM is featured in dozens of products in Japan, reflecting both the public’s confidence in its effectiveness and in the high standard of manufacture that Pharma Foods International has come to represent.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005023/en/
Contact information
Noriko Tani
info_ingredients@pharmafoods.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Expanded Indication for VONVENDI ® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 03:45:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving on-demand therapy.1 VONVENDI is now available for use in a broad range of VWD patients and is the only recombinant von Willebrand Factor (VWF) replacement therapy with approved indications in both adults and children with VWD.1 VWD is the most common bleeding disorder impacting more than 3 million people in the U.S. alone. It occurs equally among men
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20256.9.2025 00:34:00 EEST | Press release
At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology supports your life in the background so that you can live it more fully.” Samsung’s AI Home experience is designed to mak
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 18:15:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.” This report combines the previous Gartner Magic Quadrant reports for the Pri
Capcom’s Popular Title Street Fighter’s Live-Action Movie Starts Filming!5.9.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that filming has commenced on a live-action film adaptation of its popular fighting game series Street Fighter, in collaboration with Legendary Entertainment (Legendary), with both companies jointly financing the project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905806122/en/ Street Fighter Movie Title Logo To expand global sales of its core home video game software business, Capcom is actively promoting the branding of its proprietary IP under the Single Content Multiple Usage strategy. Particularly, the adaptation of game content into visual media is a valuable opportunity to broaden awareness of Capcom’s IP beyond the gaming audience. With filming of the upcoming film Street Fighter now starting, the casting of the main characters—Ken, Ryu, and Chun-Li —has been finalized. Through joint financing with Legendary, a company renowned for producing numerous blockbuster fi
Motive’s Entitlement Server Acknowledged as a Pacesetter in Counterpoint Research’s 2025 Rankings5.9.2025 16:00:00 EEST | Press release
Motive, a global leader in device management, today announced its recognition as a Pacesetter in Counterpoint Research’s 2025 Entitlement Server Rankings. Counterpoint placed Motive in its highest top-right Pacesetter quadrant: the most advanced recognition in the ranking. This accolade reflects Motive’s decisive investment in entitlement orchestration at a time when operators face urgent deadlines, including Apple’s September 2025 RCS requirement. Motive has taken the lead, proving ability to deliver at scale, currently deployed in large mobile service providers across North America, Europe, Africa, the Middle East, Asia-Pacific, and Latin America. Removing Barriers to RCS and Beyond The industry has long wrestled with the lack of a commercial framework for Rich Business Messaging (RBM) and lack of cross platform support between Android and iOS. Motive addresses this by ensuring operators can enable RCS on both Apple and Android devices securely without delay. This approach derisks op
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom